Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The central involvement of estrogen in the development of the mammary gland and in the genesis of breast cancer has lent impetus to studies of the links between estrogen action and the cell cycle machinery. Recent studies of the estrogenic regulation of molecules with known roles in the control of G1/S phase progression have resulted in significant advances in understanding these links. Estrogens independently regulate the expression and function of c-Myc and cyclin D1 and the induction of either c-Myc or cyclin D1 is sufficient to recapitulate the effects of estrogen on cell cycle progression. These pathways converge at the activation of cyclin E-Cdk2 complexes. The active cyclin E-Cdk2 complexes are depleted of the cyclin dependent kinase (CDK) inhibitor p21(WAF1/CIP1) because of estrogen-mediated inhibition of nascent p21(WAF1/CIP1). Insulin and estrogen synergistically stimulate cell cycle progression, and the ability of estrogen to antagonize an insulin-induced increase in p21(WAF1/CIP1) gene expression appears to underlie this effect. Antiestrogen treatment of MCF-7 cells leads to an acute decrease of c-Myc expression, a subsequent decline in cyclin D1, and ultimately arrest of cells in a state with features characteristic of quiescence. An antisense-mediated decrease in c-Myc expression results in decreased cyclin D1 expression and inhibition of DNA synthesis, mimicking the effects of antiestrogen treatment and emphasizing the importance of c-Myc as an estrogen/antiestrogen target. These data identify c-Myc, cyclin D1, p21(WAF1/CIP1) and cyclin E-Cdk2 as central components of estrogen regulation of cell cycle progression and hence as potential downstream targets that contribute to the role of estrogen in oncogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Estrogen receptor activation promotes cell proliferation in estrogen‐responsive tissues (breast and endometrium) [435].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [435]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wong, C.-W., McNally, C., Nickbarg, E., Komm, B. S., & Cheskis, B. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192569699 · Cited by 324
RetractedCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
Connections and Regulation of the Human Estrogen Receptor
McDonnell, D. P., & Norris, J. D. (2002) · Science · doi:10.1126/science.1071884 · Cited by 579
The myc Oncogene: arvelouslomplex
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)84004-0 · Cited by 463
Prall, O. J., Sarcevic, B., Musgrove, E. A., Watts, C. W., & Sutherland, R. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10882 · Cited by 444
Self-citationOpposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression
Liu, M.-M., Albanese, C., Anderson, C. M., Hilty, K., Webb, P., Uht, R. M., Price, R. H., Pestell, R. G., & Kushner, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201829200 · Cited by 422
Myc represses the p21 (WAF1/CIP1) promoter and interacts with Sp1/Sp3
Gartel, A. L., Ye, X., Goufman, E., Shianov, P., Hay, N., Najmabadi, F., & Tyner, A. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081074898 · Cited by 417
Rapid Actions of Steroid Receptors in Cellular Signaling Pathways
Cato, A. C. B., Nestl, A., & Mink, S. (2002) · Science's STKE · doi:10.1126/stke.2002.138.re9 · Cited by 369
Research works printed but not linked: 1
- Lai A, Sarcevic B, Prall OW & Sutherland RL 2001 Insulin/IGF-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21 WAF1/Cip1 . Journal of Biological Chemistry 276 25823-25833.
Cited by
Items 101–200 of 337
JavanMoghadam, S., Weihua, Z., Hunt, K. K., & Keyomarsi, K. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1166327 · Cited by 58
The regulatory roles of long non-coding RNAs in the development of chemoresistance in breast cancer
Malhotra, A., Jain, M., Prakash, H., Vásquez, K. M., & Jain, A. (2017) · Oncotarget · doi:10.18632/oncotarget.22577 · Cited by 60
Tan, H., Zhong, Y., & Pan, Z. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-31 · Cited by 56
Zhang, Y., Zhang, H., Liang, J., Yu, W., & Shang, Y. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601710 · Cited by 58
Wen, J., Li, R., Lu, Y., & Shupnik, M. A. (2008) · Oncogene · doi:10.1038/onc.2008.405 · Cited by 56
Dalvai, M., & Bystricky, K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011011 · Cited by 61
Rohan, T. E., Negassa, A., Chlebowski, R. T., Habel, L. A., McTiernan, A., Ginsberg, M. S., Wassertheil-Smoller, S. W., & Page, D. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn075 · Cited by 54
Gustafsson, N., Zhao, C., Gustafsson, J.-Α., & Dahlman‐Wright, K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2674 · Cited by 53
Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance
Waltersson, M. A., Nordenskjöld, B. A., Rutqvist, L. E., Skoog, L. K., & Stål, O. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-6457-4 · Cited by 52
Gut microbiota and female health
Wang, M.-Y., Sang, L.-X., & Sun, S. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i12.1655 · Cited by 54
Gulyaeva, L. F., Mikhailova, O. N., Pustylnyak, V. O., Kim, I. V., Gerasimov, A. V., Krasilnikov, S. E., Филипенко, М. Л., & Pechkovsky, E. V. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_34 · Cited by 52
FASN inhibition as a potential treatment for endocrine-resistant breast cancer
Gruslova, A., McClellan, B., Balinda, H. U., Viswanadhapalli, S., Alers, V. A., Sareddy, G. R., Huang, T. H. ‐., Garcia, M., deGraffenried, L. A., Vadlamudi, R. K., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06231-6 · Cited by 51
Santos-Martínez, N., Díaz, L., Ordaz‐Rosado, D., García‐Quiroz, J., Barrera, D., Avila, E., Halhali, A., Medina‐Franco, H., Ibarra-Sánchez, M. D. J., Esparza‐López, J., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-230 · Cited by 49
Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma
Kang, J., Qian, P., Pandey, V., Perry, J. K., Miller, L. D., Liu, E. T., Zhu, T., Liu, D., & Lobie, P. E. (2010) · Oncogene · doi:10.1038/onc.2010.71 · Cited by 50
Role of AIB1 for Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells
Su, Q., Hu, S., Gao, H., Ma, R., Yang, Q., Pan, Z., Wang, T., & Li, F. (2008) · Oncology · doi:10.1159/000159267 · Cited by 49
miR‐491‐5p functions as a tumor suppressor by targeting JMJD2B in ERα‐positive breast cancer
Hui, Z., Yiling, C., Wenting, Y., Huang, X., ChuanYi, Z., & Hui, L. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.02.014 · Cited by 50
Park, M.-A., & Choi, K. (2013) · Chemical Research in Toxicology · doi:10.1021/tx400365z · Cited by 48
Association between the microbiota and women’s cancers – Cause or consequences?
Alizadehmohajer, N., Shojaeifar, S., Nedaeinia, R., Esparvarinha, M., Mohammadi, F., Ferns, G. A., Ghayour‐Mobarhan, M., Manian, M., & Balouchi, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110203 · Cited by 53
Rotroff, D. M., Dix, D. J., Houck, K. A., Kavlock, R. J., Knudsen, T. B., Martin, M. T., Reif, D. M., Richard, A. M., Sipes, N. S., Abassi, Y. A., et al. (2013) · Chemical Research in Toxicology · doi:10.1021/tx400117y · Cited by 47
Potential anticancer activity of the medicinal herb, Rhazya stricta, against human breast cancer
Nabih, A. B., Ayman, I. E., Osama, A. A., & Mohammed, H. M. (2012) · AFRICAN JOURNAL OF BIOTECHNOLOGY · doi:10.5897/ajb12.570 · Cited by 48
Circulating Sex Steroids and Breast Cancer Risk in Premenopausal Women
Hankinson, S. E., & Eliassen, A. H. (2010) · Hormones and Cancer · doi:10.1007/s12672-009-0003-0 · Cited by 44
“It has been hypothesized to either decrease breast cancer risk, by mitigating the estrogen-induced proliferation in breast epithelial cells [68, 69], or increase risk due to the higher breast cell proliferation in the luteal phase when progesterone levels are the highest [70].”
BackgroundLinoleic Acid Upregulates Microrna-494 to Induce Quiescence in Colorectal Cancer
Ogata, R., Mori, S., Kishi, S., Sasaki, R., Iwata, N., Ohmori, H., Sasaki, T., Nishiguchi, Y., Nakashima, C., Goto, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010225 · Cited by 44
IKKα Regulates the Mitotic Phase of the Cell Cycle by Modulating Aurora A Phosphorylation
Prajapati, S., Yamamoto, Y., Gaynor, R. B., & Tu, Z. (2006) · Cell Cycle · doi:10.4161/cc.5.20.3359 · Cited by 50
Growth Factor Regulation of Cell Cycle Progression in Mammary Epithelial Cells
Stull, M. A., Rowzee, A. M., Loladze, A. V., & Wood, T. L. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023585.95430.f4 · Cited by 49
Mapping research trends in the field of knowledge management
Sedighi, M., & Jalalimanesh, A. (2014) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.14014038 · Cited by 40
IKKα Regulates Estrogen-induced Cell Cycle Progression by Modulating E2F1 Expression
Tu, Z., Prajapati, S., Park, K.-J., Kelly, N. J., Yamamoto, Y., & Gaynor, R. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512439200 · Cited by 48
Zimmermann, M., Don, A. S. A., Donaldson, M. S., Patriarchi, T., & Horne, M. C. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1243189 · Cited by 42
CCCTC-binding Factor Acts Upstream of FOXA1 and Demarcates the Genomic Response to Estrogen
Zhang, Y., Liang, J., Li, Y., Xuan, C., Wang, F., Wang, D., Shi, L., Zhang, D., & Shang, Y. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149658 · Cited by 41
Lewis, J. S., Thomas, T. J., Pestell, R. G., Albanese, C., Gallo, M. A., & Thomas, T. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01599 · Cited by 40
McGowan, E. M., Russell, A. J., Boonyaratanakornkit, V., Saunders, D. N., Lehrbach, G. M., Sergio, C. M., Musgrove, E. A., Edwards, D. P., & Sutherland, R. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1255 · Cited by 39
Self-citationDadiani, M., Seger, D., Kreizman, T., Badikhi, D., Margalit, R., Eilam, R., & Degani, H. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0249 · Cited by 38
Lee, A., Park, W. C., Yim, H. W., Lee, M. A., Park, G., & Lee, K. (2007) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hym082 · Cited by 38
Wright, P. K., May, F. E. B., Darby, S., Saif, R., Lennard, T. W. J., & Westley, B. R. (2009) · PubMed · doi:10.25405/ncl.34099989 · Cited by 43
Lata, K., & Mukherjee, T. K. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.11.014 · Cited by 37
Ruiz-Cortés, Z. T., Kimmins, S., Monaco, L., Burns, K. H., Sassone‐Corsi, P., & Murphy, B. D. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0441 · Cited by 41
Vergnaud, J., Gouilleux, F., Maillard, S., Marsaud, V., Renoir, J., & Sola, B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1668 · Cited by 39
Gadal, F., Starzec, A. B., Bozic, C., Pillot-Brochet, C., Malinge, S., Ozanne, V., Vicenzi, J., Buffat, L., Perret, G. Y., Iris, F., et al. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01631 · Cited by 39
Involvement of cyclin D1 and E2f1 in zearalenone-induced DNA damage in testis of rats
Cheraghi, S., Razi, M., & Malekinejad, H. (2015) · Toxicon · doi:10.1016/j.toxicon.2015.09.018 · Cited by 37
Cyclin D1 gene amplification is highly homogeneous in breast cancer
Burandt, E., Grünert, M., Lebeau, A., Choschzick, M., Quaas, A., Jänicke, F., Müller, V., Scholz, U., Bokemeyer, C., Petersen, C., et al. (2014) · Breast Cancer · doi:10.1007/s12282-014-0538-y · Cited by 38
Wright, P. K., Jones, S. B., Ardern, N., Ward, R. E., Clarke, R. B., Sotgia, F., Lisanti, M. P., Landberg, G., & Lamb, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1824 · Cited by 40
Malek, D., Gust, R., & Kleuser, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.01.025 · Cited by 36
Biphasic effects of zeranol on the growth of estrogen receptor-positive human breast carcinoma cells
Yuri, T., Tsukamoto, R., Miki, K., Uehara, N., Matsuoka, Y., & Tsubura, A. (2006) · Oncology Reports · doi:10.3892/or.16.6.1307 · Cited by 36
Rárová, L., Steigerová, J., Kvasnica, M., Bartůněk, P., Křížová, K., Chodounská, H., Kolář, Z., Sedlák, D., Oklešťková, J., & Strnad, M. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.017 · Cited by 36
Mammographic density and epithelial histopathologic markers
Verheus, M., Maskarinec, G., Erber, E., Steude, J., Killeen, J. L., Hernandez, B. Y., & Cline, J. M. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-182 · Cited by 35
Wang, X., Gérard, C., Thériault, J.-F., Poirier, D., Doillon, C. J., & Lin, S. (2015) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjv028 · Cited by 40
A Tale of Ice and Fire: The Dual Role for 17β-Estradiol in Balancing DNA Damage and Genome Integrity
Pescatori, S., Berardinelli, F., Albanesi, J., Ascenzi, P., Marino, M., Antoccia, A., di Masi, A., & Acconcia, F. (2021) · Cancers · doi:10.3390/cancers13071583 · Cited by 37
Estrogen Promotes Breast Cancer Cell Survival in an Inhibitor of Apoptosis (IAP)-dependent Manner
Stanculescu, A., Bembinster, L. A., Borgen, K. R., Bergamaschi, A., Wiley, E. L., & Frasor, J. M. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0018-6 · Cited by 36
Jiang, S., Katayama, H., Wang, J., Li, S. A., Hong, Y., Radvanyi, L. G., Li, J. J., & Sen, S. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0006-x · Cited by 36
Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
Onay, U. V., Aaltonen, K., Briollais, L., Knight, J. A., Pabalan, N., Kilpivaara, O., Andrulis, I. L., BLOMQVIST, C. P., Nevanlinna, H. A., & Özçelik, H. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-6 · Cited by 34
Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth
DeNardo, D. G., Cuba, V. L., Kim, H.-T., Wu, K., Lee, A. V., & Brown, P. H. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.07.006 · Cited by 40
Fiocchetti, M., Bastari, G., Cipolletti, M., Leone, S., Acconcia, F., & Marino, M. (2021) · Toxics · doi:10.3390/toxics9100237 · Cited by 35
The Effectiveness of Various Chemotherapeutic Agents in Cancer Treatment
Fathima, J. K., LAVANYA, V. A., Jamal, S., & Ahmed, N. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-022-00289-6 · Cited by 36
Tumour growth and immune evasion as targets for a new strategy in advanced cancer
Nicolini, A., Ferrari, P., Rossi, G., & Carpi, A. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0142 · Cited by 33
Combination Treatment of Tamoxifen with Risperidone in Breast Cancer
Yeh, W., Lin, H., Wu, H., & Chen, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098805 · Cited by 37
Effects of estrogen deprivation due to breast cancer treatment
Angelopoulos, N., Barbounis, V., Livadas, S., Kaltsas, D., & Tolis, G. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00783 · Cited by 38
CUL4B renders breast cancer cells tamoxifen‐resistant via miR ‐32‐5p/ ER ‐α36 axis
Wang, Y., Pan, X., Li, Y., Wang, R., Yang, Y., Jiang, B., Sun, G., Shao, C., Wang, Μ., & Gong, Y. (2021) · The Journal of Pathology · doi:10.1002/path.5657 · Cited by 31
Nagakubo, T., Demizu, Y., Kanda, Y., Misawa, T., Shoda, T., Okuhira, K., Sekino, Y., Naito, M., & Kurihara, M. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500480e · Cited by 31
Karmakar, S., Foster, E. A., & Smith, C. L. (2008) · International Journal of Cancer · doi:10.1002/ijc.24133 · Cited by 35
Lam, L. T., Hu, X., Aktary, Z., Andrews, D. W., & Pasdar, M. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0231-y · Cited by 35
The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation
Zhang, H., McElrath, T., Tong, W., & Pollard, J. W. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05987 · Cited by 35
The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance
Ferraiuolo, R., Tubman, J., Sinha, I., Hamm, C. M., & Porter, L. A. (2017) · Oncotarget · doi:10.18632/oncotarget.15578 · Cited by 37
RB·E2F1 Complex Mediates DNA Damage Responses through Transcriptional Regulation of ZBRK1*
Liao, C.-C., Tsai, C. Y., Chang, W., Lee, W., & Wang, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.143461 · Cited by 32
Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator
Shoda, T., Okuhira, K., Kato, M., Demizu, Y., Inoue, H., Naito, M., & Kurihara, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.078 · Cited by 30
Diller, M., Schüler, S., Buchholz, S., Lattrich, C., Treeck, O., & Ortmann, O. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.01.004 · Cited by 30
Das, P. M., Gupta, A., & Desai, K. V. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1028616 · Cited by 29
Cyclin D1 regulates hepatic estrogen and androgen metabolism
Mullany, L. K., Hanse, E. A., Romano, A., Blomquist, C. H., Mason, J. I., Delvoux, B., Anttila, C. K., & Albrecht, J. H. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00471.2009 · Cited by 29
Genetic heterogeneity of the MYC oncogene in advanced juvenile angiofibromas
Schick, B., Wemmert, S., Jung, V., Steudel, W.-I., Montenarh, M., & Urbschat, S. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2005.06.005 · Cited by 28
Genetic Screening Reveals an Essential Role of p27kip1 in Restriction of Breast Cancer Progression
Yuan, Y., Qin, L., Liu, D., Wu, R., Mussi, P., Zhou, S., Songyang, Z., & Xu, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0083 · Cited by 28
Hurtado, A., Pinós, T., Barbosa-Desongles, A., López‐Avilés, S., Barquinero, J., Pétriz, J., Santamaria‐Martínez, A., Moróte, J., de Torres, I. M., Joaquim Bellmunt, B., et al. (2008) · Analytical Cellular Pathology · doi:10.1155/2008/129726 · Cited by 28
ISHIDA, Y., Zhao, D., Ohkuchi, A., Kuwata, T., YOSHITAKE, H., Yuge, K., Takizawa, T., Matsubara, S., Suzuki, M., Saito, S., et al. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2157 · Cited by 32
Association between Melanocytic Nevi and Risk of Breast Diseases: The French E3N Prospective Cohort
Kvaskoff, M., Bijon, A., Mesrine, S., Vilier, A., Baglietto, L., Fournier, A., Clavel‐Chapelon, F., Dossus, L., & Boutron‐Ruault, M. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001660 · Cited by 27
Prenylflavonoids as Nonsteroidal Phytoestrogens and Related Structure–Activity Relationships
Wang, Z., Weber, N., Lou, Y., & Proksch, P. (2006) · ChemMedChem · doi:10.1002/cmdc.200500089 · Cited by 27
Demizu, Y., Misawa, T., Nagakubo, T., Kanda, Y., Okuhira, K., Sekino, Y., Naito, M., & Kurihara, M. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.06.067 · Cited by 27
Cepa, M., Correia‐da‐Silva, G., da Silva, E. J. T., Roleira, F. M. F., Borges, M. C., & Teixeira, N. A. A. (2008) · BMC Cell Biology · doi:10.1186/1471-2121-9-41 · Cited by 26
Renoir, J., Bouclier, C., Seguin, A., Marsaud, V., & Sola, B. (2008) · Journal of Molecular Endocrinology · doi:10.1677/jme-07-0143 · Cited by 28
Cañas, A., Lopez-Sanchez, L. M., Valverde, A. M., Hernandez, V. A., Fuentes, E., Muñoz-Castañeda, J. R., López-Pedrera, C., de la Haba-Rodríguez, J., Aranda, E., & Rodríguez‐Ariza, A. (2012) · Breast Cancer Research · doi:10.1186/bcr3366 · Cited by 28
Sims, H. I., Lane, J. M., Ulyanova, N. P., & Schnitzler, G. R. (2007) · Biochemistry · doi:10.1021/bi7008823 · Cited by 28
Park, J. H., Lee, M. Y., & Han, H. J. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.07.010 · Cited by 25
Targeting the Ubiquitin–Proteasome Pathway In Breast Cancer Therapy
Dees, E. C., & Orlowski, R. Z. (2006) · Future Oncology · doi:10.2217/14796694.2.1.121 · Cited by 25
Park, M.-A., Hwang, K., Lee, H.-R., Yi, B.-R., & Choi, K. (2011) · Toxicological Research · doi:10.5487/tr.2011.27.4.253 · Cited by 24
Yaacob, N. S., Kamal, N. N. N. M., Wong, K. K., & Norazmi, M. N. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.18.8135 · Cited by 24
Natural Products for the Prevention, Treatment and Progression of Breast Cancer
Svolacchia, F., Brongo, S., Catalano, A. A., Ceccarini, A., Svolacchia, L., Santarsiere, A., Scieuzo, C., Salvia, R., Finelli, F., Milella, L., et al. (2023) · Cancers · doi:10.3390/cancers15112981 · Cited by 23
Nigam, M., Singh, N., Ranjan, V., Zaidi, D., Sharma, R., Nigam, D., Gupta, D. K., Sundaram, S., & Balapure, A. K. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.10.015 · Cited by 23
Toillon, R., Magné, N., Laïos, I., Lacroix, M., Duvillier, H., Lagneaux, L., Devriendt, D., Houtte, P. V., & Leclercq, G. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-5148-0 · Cited by 23
Mechanistic Effects of Estrogens on Breast Cancer
Santen, R. J., Stuenkel, C. A., & Yue, W. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000596 · Cited by 23
Nicolini, A., Ferrari, P., Silvestri, R., & Gemignani, F. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.01.004 · Cited by 25
Zheng, Y., & Murphy, L. C. (2016) · Nuclear Receptor Signaling · doi:10.1621/nrs.14001 · Cited by 22
Takai, N., Ueda, T., Nasu, K., Yamashita, S., Toyofuku, M., & Narahara, H. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.12.018 · Cited by 22
RetractedKalabay, M., Szász, Z., Láng, O., Lajkó, E., Pállinger, É., Duró, C., Jernei, T., Csámpai, A., Takács, A., & Kőhidai, L. (2022) · Pharmaceuticals · doi:10.3390/ph15030314 · Cited by 21
Zhang, C., Wang, S., Moura, M. C., Yi, E. S., Bowen, A. J., Specks, U., Warrington, K. J., Bayan, S. L., Ekbom, D. C., Luo, F., et al. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.07.005 · Cited by 21
An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management
Khallouki, F., Hajji, L., Saber, S., Bouddine, T., Edderkaoui, M., Bourhia, M., Mir, N., Lim, A., Midaoui, A. E., Giesy, J. P., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050754 · Cited by 28
Zamir‐Nasta, T., Pazhouhi, M., Ghanbari, A., Abdolmaleki, A., & Jalili, C. (2021) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.310525 · Cited by 20
Physical Activity in the Prevention and Therapy of Breast Cancer
Gräf, C., & Wessely, N. (2010) · Breast Care · doi:10.1159/000322650 · Cited by 25
Endogenous Sex Hormones and Breast Density in Young Women
Jung, S., Stanczyk, F. Z., Egleston, B. L., Snetselaar, L., Stevens, V. J., Shepherd, J., Horn, L. V., LeBlanc, E. S., Paris, K., Klifa, C. S., et al. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0939 · Cited by 20
Liu, Z., Wang, L., Yang, J., Bandyopadhyay, A. M., Kaklamani, V., Wang, S., & Sun, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9772 · Cited by 22
Liang, J., Zhang, H., Zhang, Y., Zhang, Y., & Shang, Y. (2008) · EMBO Reports · doi:10.1038/embor.2008.223 · Cited by 20
Urbinati, G., Audisio, D., Marsaud, V., Plassat, V., Arpicco, S., Sola, B., Fattal, E., & Renoir, J. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-0023-z · Cited by 18
Englert, N. A., Spink, B. C., & Spink, D. C. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.12.010 · Cited by 19
Plourde, M., Ferland, A., Soucy, P., Hamdi, Y., Tranchant, M., Durocher, F., Sinilnikova, O. M., The, V. L., & Simard, J. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.05.005 · Cited by 21
Kim, S., Singh, K. B., Hahm, E., & Singh, S. V. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0590 · Cited by 17
Metadata
- Authors
- Doisneau-Sixou, S. F., Sergio, C. M., Carroll, J. S., Hui, R., Musgrove, E. A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, R L
- Venue
- Endocrine Related Cancer
- Publisher
- Bioscientifica
- Published
- 2003-06-01
- Volume
- 10
- Issue
- 2
- Pages
- 179-186
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2121155074
- Cited by
- 333
- References
- 53
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 12 · 2023: 16 · 2022: 17 · 2021: 15 · 2020: 8 · 2019: 8 · 2018: 14 · 2017: 9 · 2016: 15 · 2015: 13 · 2014: 17 · 2013: 7 · 2012: 9
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- National Health and Medical Research Council
- Cancer Council NSW
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- estrogen, antiestrogens, breast cancer, cell cycle progression, c-Myc, cyclin D1, p21, cyclin E/CDK2, G1/S phase, MCF-7 cells, quiescence, carcinogenesis, cyclin-dependent kinase inhibitors
- MeSH terms
- Animals, Breast Neoplasms, Cell Cycle, Estrogens, Female, Humans, Cyclins, Proto-Oncogene Proteins c-myc, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Cyclin-Dependent Kinases, Cyclin E, Cyclin D1, Estrogen Receptor Modulators, CDC2-CDC28 Kinases, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.